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Endoscopic Submucosal Dissection for Recurrent or Residual 
Superficial Esophageal Cancer after Chemoradiotherapy: Two Cases
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Korea
We report two cases of endoscopic submucosal dissection (ESD) for recurrent or residual esophageal squamous cell carcinoma (ESCC) 
lesions after chemoradiotherapy for advanced esophageal cancer. Case 1 involved a 64-year-old man who had previously undergone 
chemoradiotherapy for advanced ESCC and achieved a complete response (CR) for 22 months, until metachronous recurrent 
superficial ESCC was detected on follow-up esophagogastroduodenoscopy (EGD). We performed ESD and found no evidence of 
recurrence for 24 months. Case 2 involved a 59-year-old man who had previously undergone chemoradiotherapy for advanced ESCC. 
He responded favorably to treatment, and most of the tumor had disappeared on follow-up EGD 4 months later. However, there were 
two residual superficial esophageal lugol-voiding lesions. We performed ESD, and he had a CR for 32 months thereafter. ESD can be 
considered a viable treatment option for recurrent or residual superficial ESCC after chemoradiotherapy for advanced esophageal 
cancer. Clin Endosc  2015;48:553-557
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INTRODUCTION
Chemoradiotherapy (CRT) is the preferred primary treat-
ment modality for esophageal squamous cell carcinoma 
(ESCC). However, about 13% of patients treated for ESCC 
with CRT have residual tumor or experience recurrence after 
treatment.1,2 The optimal treatment method for local recur-
rence remains controversial. Surgery is suggested as a salvage 
therapy for such patients; however, the high mortality and 
morbidity rates associated with this approach are a cause for 
concern.2 Recently, several authors have reported favorable 
outcomes with esophageal endoscopic submucosal dissection 
(ESD) for recurrent ESCC after CRT.3,4 En bloc resection of 
mucosal lesions can be achieved with ESD. In addition, ESD 
is an effective and relatively safe treatment for ESCC.5,6 Al-
though ESCC is responsive to CRT, CRT monotherapy can 
sometimes result in local recurrence.7 In the present study, we 
used ESD for recurrent and residual ESCC lesions after CRT 
for advanced esophageal cancer.
CASE REPORTS
Case 1
A 64-year-old man visited our department with a complaint 
of dysphagia and chest discomfort that had been present for 
1 month. Esophagogastroduodenoscopy (EGD) revealed an 
esophageal ulcerofungating mass 24 cm from the incisors 
(Fig. 1A); the scope could not be passed beyond the lesion. 
The biopsy report revealed moderately differentiated invasive 
squamous cell carcinoma (SCC).
Computed tomography (CT) and positron emission tomog-
raphy (PET) showed subcarinal lymph node metastasis; how-
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ever, there was no other lymph node involvement or distant 
metastasis (Fig. 1B). The tumor was staged as T3N1M0, and 
CRT was performed. The chemotherapy regimen included 12 
courses of 750 mg/m2/day 5-fluorouracil (5-FU) plus 20 mg/
m2/day cisplatin for 5 days. One cycle of chemotherapy lasted 
for 4 weeks. Cisplatin was discontinued because of neuropathy 
from the eighth chemotherapy cycle. Radiotherapy including 
63-Gy doses in 35 fractions was concurrently delivered during 
the first and second chemotherapy cycles. He showed a com-
plete response (CR) after CRT. We assessed him with EGD 
every 6 months, and each examination until the 16-month 
follow-up revealed only scar tissue at the mid-esophagus. 
The pathological examination of the esophageal scar tissue 
revealed only glycogenic acanthosis. However, the follow-up 
EGD at 22 months revealed metachronous recurrence, in-
cluding an 11-mm superficial esophageal lugol-voiding lesion 
33 cm from the incisors, which was involved in the previous 
radiation field (Fig. 1C). This lesion was pathologically identi-
fied as SCC. We then performed endoscopic ultrasonography, 
which showed that the lesion was confined to the mucosal 
Fig. 1. Initial esophagogastroduodenoscopy and positron emission tomography (PET) findings of case 1. (A) Esophageal mass lesion 24 cm from the incisors 
causing malignant stricture; the scope could not reach past the lesion. (B) PET image showing esophageal cancer at the mid to distal portion with paraesophageal 
invasion, including invasion of the subcarinal lymph node. (C) Image showing the radiation field.
A B C
23 cm from incisor 
32 cm from incisor 
Fig. 2. Esophagogastroduodenoscopy procedure and pathologic findings of case 1. (A, B) Salvage endoscopic submucosal dissection (ESD) for metachronous 
recurrent superficial esophageal squamous cell carcinoma. The lesion is 32 cm from the incisors and previously treated with radiation. (C) The pathologic finding of 
the ESD specimen showing a well-differentiated squamous cell carcinoma with lamina propria invasion. Ulceration with dilated vessels (white arrows), inflammatory 
infiltrates (black arrow), and mild fibrosis (arrowhead) in the lamina propria, so-called radiation change, are noted (H&E stain, ×200).
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C
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layer with an intact submucosal layer. We performed ESD 
for metachronous recurrent ESCC. A submucosal cushion 
was established through the submucosal injection of a solu-
tion consisting of a mixture of sodium hyaluronate (LG Life 
Science Co., Seoul, Korea), 10% glycerol, and 5% fructose in 
normal saline solution (Cerol; JW Pharmaceutical Co., Seoul, 
Korea); a small amount of epinephrine; and indigo carmine. 
Mucosal cutting and submucosal dissection were performed 
with a dual knife (KD-650Q; Olympus, Tokyo, Japan). The 
fibrosis in the submucosal layer was very subtle; submucosal 
dissection was performed without complications; and en bloc 
resection was achieved within 25 minutes (Fig. 2). The final 
pathology results showed well-differentiated SCC with neg-
ative basal and lateral resection margins, and invasion to the 
depth of the lamina propria (Fig. 2C). We assessed him at reg-
ular follow-ups with EGD, chest CT, and PET after ESD. Each 
EGD result showed only scar tissue that was histologically 
negative for cancer cells. Until 24 months after ESD, follow-up 
CT and PET scans showed no evidence of local recurrence or 
distant metastasis.
Fig. 4. Esophagogastroduodenoscopy procedure and pathologic finding of case 2. (A, B) Endoscopic submucosal dissection (ESD) en bloc  resection of the residual 
superficial lugol-voiding lesion 38 cm from the incisors. (C) The pathologic finding of the ESD specimen showing a well-differentiated squamous cell carcinoma with 
lamina propria invasion. Dilated vessels (white arrow), inflammatory infiltrates (black arrow), and mild fibrosis (arrowhead) in the lamina propria are shown (H&E stain, 
×200).
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Fig. 3. Initial esophagogastroduodenoscopy (EGD) and positron emission tomography (PET) findings of case 2. (A) EGD image showing an esophageal ulcerofun-
gating mass. (B) PET scan showing a large esophageal lesion 29 to 43 cm from the incisors and metastasis to the left supraclavicular lymph node (white arrows).  (C) 
Image showing the radiation field.
A                                                     B                                                         C
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Case 2
A 59-year-old man visited our department with a complaint 
of dyspepsia and chest discomfort that had been present for 
3 months. We performed EGD and found a large esophageal 
ulcerofungating mass 29 to 43 cm from the incisors (Fig. 3A). 
The biopsy results confirmed SCC with an uncertain level of 
invasiveness.
CT and PET showed metastasis to the left supraclavicular 
lymph node and multiple lymph nodes at the mediastinum 
(Fig. 3B). The mass was staged as T4N3M1a, and CRT was 
performed. The chemotherapy regimen included 12 courses of 
750 mg/m2/day 5-FU plus 20 mg/m2/day cisplatin for 5 days. 
One cycle of chemotherapy lasted for 4 weeks. Radiotherapy 
at 54 Gy was delivered in 30 fractions concurrently during the 
first and second chemotherapy cycles (Fig. 3C). He responded 
favorably, and most of the mass disappeared after CRT. EGD 
at 4 months after CRT showed fibrotic scars 29 to 43 cm from 
the incisors. However, there were still two small residual su-
perficial esophageal lugol-voiding lesions 38 and 43 cm from 
the incisors, respectively, and biopsy results revealed moder-
ate- to high-grade squamous dysplasia. EGD at 5 months after 
CRT still showed mostly fibrotic scars at the previous lesion 
location; however, two (23×17 and 18×12 mm) superficial lu-
gol-voiding lesions remained 38 and 43 cm from the incisors, 
respectively, which were located within the initial advanced 
ESCC margins (14 cm long). We performed ESD for the 
two residual lesions. A submucosal cushion was established 
through the submucosal injection of a solution composed of a 
mixture of sodium hyaluronate (LG Life Science), 10% glycer-
ol, and 5% fructose in normal saline solution (Cerol); a small 
amount of epinephrine; and indigo carmine. Mucosal cutting 
and submucosal dissection were performed with a dual knife 
(KD-650Q). Although ESD for these lesions showed mild 
submucosal fibrosis caused by the earlier CRT, we achieved 
en bloc resection for both lesions without any complications 
within 55 minutes (Fig. 4). The final pathology results revealed 
well-differentiated SCC confined within the lamina propria 38 
cm from the incisors, and high-grade squamous dysplasia 43 
cm from the incisors. The resection margins were all negative 
(Fig. 4C). We followed him regularly with EGD, chest CT, and 
PET after ESD. Each EGD result showed only scar tissue that 
was histologically negative for cancer cells. Until 32 months 
after ESD, follow-up CT and PET showed no evidence of local 
recurrence or distant metastasis.
DISCUSSION
It is challenging to completely cure locally recurrent or 
residual ESCC after CRT.1,2 The optimal treatment for these 
lesions is controversial; however, recent studies have shown 
that ESD could be an option.2-4 Saito et al.3 reported that ESD 
can be used for the en bloc resection of recurrent or residual 
superficial esophageal tumors after CRT, with a high rate of 
CR and without greater risk than for endoscopic mucosal 
resection. They used ESD to treat four patients with local re-
currence of ESCC, and successfully achieved en bloc resection 
in all patients. Furthermore, Takeuchi et al.8 reported that ESD 
represents an acceptable treatment option for recurrent or 
residual ESCC involving only the submucosal layer without 
metastasis after CRT because of its effect in improving local 
control. They successfully treated 19 lesions in 19 patients 
who underwent salvage ESD. At a median follow-up of 54.6 
months, no local recurrence was noted at the treatment site in 
any patient. The 3-year overall survival rate after salvage ESD 
was 74%.8 Koizumi et al.9 also reported 12 cases of salvage 
ESD for esophageal SCC after a definitive CRT. The median 
survival duration after salvage ESD for all patients was 18 
Table 1. Summary of the Outcomes of Endoscopic Submucosal Dissection after Chemoradiotherapy
Variable Takeuchi et al.(2013)8
Koizumi et al.
(2014)9
Saito et al.
(2008)3 Present study
No. of patients 19 12 4 2
Age, yr 71 (52–91) 67 (55–79) NA NA (59–64)
Sex, male:female 18:1 NA NA 2:0
Recurrent:Residual 15:4 12:0 2:2 1:1
Tumor-free margin 18 (95) 11 (92) 3 (75) 2 (100)
En bloc rate 19 (100) 11 (92) 4 (100) 2 (100)
Follow-up time, mo 54.6 (5–98) 25.75±17 3 (0–6) 28±4
Survival at the last follow-up 10 (52.6) 9 (75) 4 (100) 2 (100)
3-Year overall survival rates, % 74 NA NA NA
Values are presented as median (range), number (%), or mean±SD.
NA, not applicable.
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months (range, 8 to 70), and 9 of 12 patients have survived.9 
Table 1 shows a summary of the findings of the three previous 
reports along with the findings in our cases.
Esophageal ESD for ESCC is not an easy procedure. A high 
level of technical skill is necessary to achieve en bloc resection 
and to avoid complications such as perforation. Moreover, 
when there is fibrosis in the submucosal layer, esophageal 
ESD becomes more technically demanding. Because CRT 
induces some fibrosis in the esophageal wall, fibrosis at the 
treatment location can be predicted. This makes ESD proce-
dures difficult, and frequently leads to complications. There 
are concerns about the technical difficulty of ESD and possi-
ble complications from ESD after CRT. Although data on the 
outcomes of esophageal ESD after CRT are limited, several 
Japanese authors have reported favorable outcomes for esoph-
ageal ESD after CRT.3,8-10 In addition, our two patients showed 
favorable outcomes without complications. Safe management 
of mild fibrosis caused by CRT and acceptable outcomes can 
be achieved depending on technical skill of the ESD endosco-
pists.
In this report, we presented two cases of recurrent and 
residual ESCC treated successfully with ESD after CRT. No 
complications such as perforation or major bleeding were ob-
served. With a longer follow-up duration, tumors may recur 
at the original site; however, there has been no recurrence for 
26 months in case 1 and for 32 months in case 2. Although it 
requires patients to be assessed for a long period, salvage ESD 
can be considered an effective and safe treatment option that 
requires a certain level of technical expertise when locore-
gional failure is limited to the mucosal layer with no distant 
metastases.
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